Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
Molecular substratification of endometrial carcinomas with no special molecular profile (NSMP) by using a limited NGS custom panel may facilitate effective patient selection for the PIK3CA-targeted therapy.
Ondič O et al.
Virchows Archiv : an International Journal of Pathology, 2025
AutoEpiCollect, a Novel Machine Learning-Based GUI Software for Vaccine Design: Application to Pan-Cancer Vaccine Design Targeting PIK3CA Neoantigens.
Samudrala M et al.
Bioengineering (basel, Switzerland), 2024
Clinicopathological characteristics and genetic analysis of pulmonary carcinoid tumors: A single-center retrospective cohort study and literature review.
Li X et al.
Oncology Letters, 2020
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Razia S et al.
Experimental and Therapeutic Medicine, 2019
Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.
Capodanno A et al.
Oncology Reports, 2012
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Ligresti G et al.
Cell Cycle (georgetown, Tex.), 2009
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009
19139070 (PubMed )
Supplement: gkn1008_nar-01723-s-2008-File009.xls › TypeI-
Select a paper to view details